Piccinelli Mattia Luca, Law Kyle, Incesu Reha-Baris, Tappero Stefano, Cano Garcia Cristina, Barletta Francesco, Morra Simone, Scheipner Lukas, Baudo Andrea, Tian Zhe, Luzzago Stefano, Mistretta Francesco Alessandro, Ferro Matteo, Saad Fred, Shariat Shahrokh F, Carmignani Luca, Ahyai Sascha, Longo Nicola, Briganti Alberto, Chun Felix K H, Terrone Carlo, Tilki Derya, de Cobelli Ottavio, Musi Gennaro, Karakiewicz Pierre I
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H2X 3E4, Canada.
Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Cancers (Basel). 2024 Sep 29;16(19):3331. doi: 10.3390/cancers16193331.
BACKGROUND/OBJECTIVES: Solitary fibrous tumors (SFTs) represent a rare mesenchymal malignancy that can occur anywhere in the body. Due to the low prevalence of the disease, there is a lack of contemporary data regarding patient demographics and cancer-control outcomes.
Within the SEER database (2000-2019), we identified 1134 patients diagnosed with malignant SFTs. The distributions of patient demographics and tumor characteristics were tabulated. Cumulative incidence plots and competing risks analyses were used to estimate cancer-specific mortality (CSM) after adjustment for other-cause mortality.
Of 1134 SFT patients, 87% underwent surgical resection. Most of the tumors were in the chest (28%), central nervous system (22%), head and neck (11%), pelvis (11%), extremities (10%), abdomen (10%) and retroperitoneum (6%), in that order. Stage was distributed as follows: localized (42%) vs. locally advanced (35%) vs. metastatic (13%). In multivariable competing risks models, independent predictors of higher CSM were stage (locally advanced HR: 1.6; metastatic HR: 2.9), non-surgical management (HR: 3.6) and tumor size (9-15.9 cm HR: 1.6; ≥16 cm HR: 1.9).
We validated the importance of stage and surgical resection as independent predictors of CSM in malignant SFTs. Moreover, we provide novel observations regarding the independent importance of tumor size, regardless of the site of origin, stage and/or surgical resection status.
背景/目的:孤立性纤维瘤(SFT)是一种罕见的间叶源性恶性肿瘤,可发生于身体的任何部位。由于该疾病的发病率较低,缺乏关于患者人口统计学和癌症控制结局的当代数据。
在监测、流行病学和最终结果(SEER)数据库(2000 - 2019年)中,我们确定了1134例被诊断为恶性SFT的患者。将患者人口统计学和肿瘤特征的分布制成表格。使用累积发病率图和竞争风险分析来估计在调整其他原因死亡率后的癌症特异性死亡率(CSM)。
在1134例SFT患者中,87%接受了手术切除。大多数肿瘤依次位于胸部(28%)、中枢神经系统(22%)、头颈部(11%)、骨盆(11%)、四肢(10%)、腹部(10%)和腹膜后(6%)。分期分布如下:局限性(42%)、局部进展期(35%)、转移性(13%)。在多变量竞争风险模型中,较高CSM的独立预测因素为分期(局部进展期风险比:1.6;转移性风险比:2.9)、非手术治疗(风险比:3.6)和肿瘤大小(9 - 15.9 cm风险比:1.6;≥16 cm风险比:1.9)。
我们验证了分期和手术切除作为恶性SFT中CSM独立预测因素的重要性。此外,我们提供了关于肿瘤大小的独立重要性的新观察结果,而不考虑肿瘤起源部位、分期和/或手术切除状态。